Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
about
Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute DecompensatedChallenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsIntestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitideAssociation between fluid balance and survival in critically ill patientsRenal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failureWater and sodium in heart failure: a spotlight on congestionCommonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey.Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated Heart Failure TreatmentDiscovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.Diuretic strategies in patients with acute decompensated heart failure.Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure.Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failureObesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudyInfluence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure.Approaches to decongestion in patients with acute decompensated heart failure.Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure.Can we improve the treatment of congestion in heart failure?Novel therapeutic targets for the treatment of heart failure.The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?Cardiorenal syndrome and the role of ultrafiltration in heart failure.Clinical utility of antigen carbohydrate 125 in heart failure.Treatment of acute heart failure in the emergency department.Vasopressin receptor antagonists: from pivotal trials to current practice.Prehospital use of furosemide for the treatment of heart failure.Underutilization of IV nitrates in the treatment of acute heart failure.Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESCTrajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).Turning Failure into Success: Trials of the Heart Failure Clinical Research Network.Treatment Considerations and the Role of the Clinical Pharmacist Throughout Transitions of Care for Patients With Acute Heart FailureEffects of tolvaptan in patients with chronic kidney disease and chronic heart failure.Sympathetic crashing acute pulmonary edema.Advances in chemical pharmacotherapy for managing acute decompensated heart failure.[Modern drug therapy in cardiovascular intensive care medicine].Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.
P2860
Q27340297-5F6C2C5D-0D5E-4F5F-A235-8AD4B579EE8BQ28085736-2467ED2C-B5F2-44F1-A7E1-8A889FB638BDQ34409745-BF019005-3E13-4C55-89E5-E8C8578B1026Q34486006-3DE70D1B-904E-4A2E-B1F3-3214AC8DAF7CQ34643664-60C2E539-EC4E-40CD-91FF-4F5E22E9F7C5Q34696390-89512AAA-CC06-4D42-907C-C91745CB472FQ35070734-8046720A-F080-4E22-821B-05F37DABE59CQ35071595-64308E00-69C3-43CB-9BEF-C3019C5A15C2Q35510429-C6EAEA5F-4FE0-48D4-BEA2-5B3F6018554BQ35643437-899838BA-6985-4171-BEF8-1C10D7C640CEQ35762752-3C4DAF56-838F-4F9A-A263-1A1DBBD3E12FQ35844551-EAD516C2-8AB2-41C6-8FB4-5D32FEAB73BCQ36141962-73AAE69E-199F-44B8-82B8-A331099D4111Q36178412-112FC813-66C6-4052-ABF7-EB5EF83E3F7DQ36243378-61D84231-F2B2-4E2D-AEA8-8EEA1F81A2E2Q36315462-B161D627-1F89-4EBA-A197-0551DB9E1865Q36399698-1B012684-5E18-48EC-B0EF-E253BCCA4476Q36543908-E3632FA0-07A9-4A41-A6B4-683F9FB396B6Q36694354-9DADA546-55DB-4CE7-B04F-5B09E12338FDQ37397960-B4609AE8-7517-479C-99C4-0271959645BCQ37419451-522C57F1-78C1-40CE-A01D-21C35BC9F174Q37509203-DEC45305-3D69-4638-8077-0B3F0E0E8194Q37845856-6D769339-C7E0-4AA1-9A35-5D376A8D33D5Q37893956-1C9C4DA4-1F77-4A19-942D-B575C2C0F3CBQ37956552-609BF0F9-EF97-4DE4-8765-B5262727492BQ38077123-AF19EE5A-39CE-4E3D-AE31-D7FFAA77C76AQ38127350-528BDC27-30E2-462D-B809-3A7AAD2F8404Q38145265-36CC5485-70FE-4729-996F-43AF46D6DFB6Q38160378-2FEBAB2E-0F0F-4BFD-A61C-A48990A8162EQ38202545-1FFD52A5-564A-4D10-9C82-88397D7A9A17Q38485493-223420B5-D38A-4E14-A919-AF79EBA36C48Q38676886-379A8EC4-3CFD-4087-AA23-978B3D04FD99Q38799792-A3195672-CE56-4685-A368-C9FA400E2FD0Q38802222-496BBC30-7B1A-4CF9-B153-60CFBBD1C6F5Q38821193-E91AB7A2-5F84-409C-A5DC-8BDB04E6ADEAQ38965320-064EBE22-4ECD-4AF6-BABC-71DBFCCE3F73Q39114192-6DF34E89-C151-4DC6-A364-1629B0CF8AEBQ39158670-691C4F26-0A75-4E32-8F17-C9B6660EC89EQ39188101-51B07AFE-9177-4FB1-9339-58AE0222568BQ39224155-8812AEB7-2CBF-44C3-A748-16D482CCF966
P2860
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@en
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@nl
type
label
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@en
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@nl
prefLabel
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@en
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@nl
P2860
P1476
Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?
@en
P2093
G Michael Felker
Heart Failure Clinical Research Network Investigators
P2860
P356
10.1161/CIRCHEARTFAILURE.108.821785
P577
2009-01-01T00:00:00Z